Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KRBA1 (KRAB-A domain containing 1) is a human protein containing a KRAB (Kruppel-associated box) domain and multiple C2H2-type zinc finger motifs, characteristic of KRAB domain zinc finger transcription factors[1][2][3]. The KRAB domain acts as a strong transcriptional repressor by recruiting corepressor proteins such as KAP-1/TRIM28, which in turn assemble chromatin-modifying complexes to silence gene expression[1][2][3]. KRAB domain proteins are vertebrate-specific and function in regulation of transcription, chromatin structure, cell proliferation, differentiation, and apoptosis[1][2]. While KRAB-ZFPs play significant regulatory roles and are implicated in cancer by virtue of their involvement in cell cycle and apoptosis[1][2], there is no direct evidence that KRBA1, or the ambiguous "KRAB domain containing 3," is a validated therapeutic drug target, nor is its involvement with pharmacological agents or clinical biomarkers documented.
No mechanism of action described for drugs targeting KRBA1/KRABD3; general KRAB-ZFP mechanism involves transcriptional repression via corepressor KAP-1/TRIM28 recruitment[1][2][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on KRAB-A domain containing 1 (KRBA1).